Kintara surges on 'fast track' tag for cancer therapy

TuHURA Biosciences

15/06/2022 15:28

** Shares of drug developer Kintara Therapeutics  KTRA.O 
rise ~43% to $0.26
    ** Co says U.S. FDA has granted "fast track" designation to
its lead drug candidate for treating newly diagnosed
glioblastoma (GBM), an aggressive cancer of the brain or spinal
cord  urn:newsml:reuters.com:*:nPn648LM4a
    ** The tag is meant to speed up development and review of
therapeutics intended to treat serious or life-threatening
conditions
    ** The drug, VAL-083, is being tested in a mid-to-late stage
study in patients with newly diagnosed and recurrent GBM; co
expects to report data by end of 2023
    ** Including session moves, stock down ~48.4% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))